3:19pm

Mon September 24, 2012
Shots - Health Blog

Experimental Drug Is First To Help Kids With Premature Aging Disease

Originally published on Tue September 25, 2012 5:11 pm

Researchers have found the first drug to treat progeria, an extremely rare genetic disease that causes children to age so rapidly that many die in their teens.

The drug, called lonafarnib, is not a cure. But in a study published Monday of 28 children, it reversed changes in blood vessels that usually lead to heart attacks and strokes.

The treatment also helped kids with the disease put on weight and improved the structure of their bones. Children with progeria have small fragile bodies and can weigh just a third of a typical child their age.

"This is a fantastic first step," says Leslie Gordon, medical director for the Progeria Research Foundation and the mother of a child with progeria. A second study is under way to see whether combining lonafarnib with two other drugs will work even better, says Gordon, who is also a physician on the faculty of Boston Children's Hospital and Brown University.

The research that led to the drug also has led to a better understanding of how aging takes place in individual cells, Gordon says.

But perhaps the most remarkable thing about the new treatment is how fast it was developed. Just a decade ago, researchers didn't even know what caused progeria, let alone how to treat it.

The quick pace of research is in large part the result of Leslie Gordon and her husband, Scott Berns, who is also a physician.

Their son, Sam, was diagnosed with progeria in 1998, shortly before he turned 2. At the time, they knew very little about progeria, which affects perhaps 100 people worldwide. And what the experts told them was discouraging, Gordon says.

"All children, we were told, die of heart attacks or strokes between the ages of maybe 7 and 20 years," she says. "Nobody knew the cause. No one was working on this and we were nowhere. There was no place for us to go to understand what was happening with our child."

So Gordon and her husband set out to find the cause of this rare disease, and a cure. They started a foundation. Gordon began doing research on progeria. But things might have gone slowly without some help from a scientist named Francis Collins.

Collins is not just any scientist. These days he runs the National Institutes of Health. Back then he was in charge of the government's effort to map the human genome. And early in his career, Collins actually cared for a patient with progeria.

"It was a fascinating circumstance but a very frustrating one because there was nothing much known about the disease," he says. "So I didn't quite know what to offer this wonderful young woman."

The woman died in her 20s. But Collins never forgot her. "And then I met Leslie and her husband, Scott, and learned that they had a son with this condition," he says.

So Collins joined a consortium of genetic scientists set up by Gordon's foundation. He also asked a researcher in his lab to look for a genetic cause of the disease. He gave her a year.

"And in substantially less than a year we had the answer," Collins says, thanks to "a combination of a very good post-doc, a pretty good strategy, and a little good luck along the way."

The cause was a single, chance mutation on a single gene. Just one misplaced letter out of billions in the genetic code was leading to the production of a toxic protein that makes cells age prematurely.

Finding the cause of a genetic disease does not necessarily lead to a treatment. But in this case, Collins says, scientists had spent decades studying the gene where the error occurred.

"And it was really within only a short time after realizing what the problem was that we were also able to make a hypothesis about what might help," Collins says

All that happened about five years after Sam was diagnosed. And by this time, Sam was in grade school and living a pretty normal life, Gordon says.

"Sam was acting like his age. And he had friends his own age," she says. "He was just much, much smaller than the rest of his friends and, yes, he had no hair. But that doesn't matter to your friends. And so he was going to school and growing up and doing, actually fantastic."

Even so, Gordon knew she was in a race against time.

At this point, researchers thought they knew what sort of drug might protect cells from the toxic protein that causes progeria. Developing a drug like that from scratch could have taken many years.

But by chance, pharmaceutical companies already had some drugs in production that looked like good candidates. These were experimental cancer drugs that just happened to affect the same process involved in progeria.

"Again, we got lucky because there was 10 years' worth of pharmaceutical research into developing a drug that we asked to be moved over into the field of progeria," Gordon says.

But the progeria team needed help from someone who understood these unusual cancer drugs. Enter Mark Kieran, a pediatric brain cancer specialist at Boston Children's Hospital and the Dana Farber Cancer Institute.

"There were only a couple of people in the world that had been testing these drugs and one of them was me," Kieran says."

By the time Kieran got involved around 2006, researchers had already shown that a drug called lonafarnib could help mice with the progeria gene.

"They now had all of the science," Kieran says. "What they had never done before was actually figure out how to move it into the clinic to treat kids. And since that's what I do everyday, that's where we were able to kind of put our expertise together to make this thing happen."

It happened fast. The study began in 2007 and was designed to run for several years. It included 28 children from 16 countries, including Sam.

The results appear in the Proceedings of the National Academy of Sciences, and they are encouraging. Overall, lonafarnib helped children gain weight and improve their bone structure. But more important, Gordon says, it has reversed changes in blood vessels associated with the heart attacks and strokes that usually kill kids with progeria.

"That was an absolutely home run pivotal finding for our study," she says.

This drug isn't a cure. But it's an important first step, Gordon says. And she notes that researchers have already moved on to a second study using lonafarnib and two other drugs.

The race against progeria has been run to benefit just a few dozen children around the globe. But there's been an unexpected payoff for the rest of humanity. Research on the toxic protein responsible for progeria is changing scientists' understanding of how normal cells age.

"It has told us something pretty profound, namely that all of us are making little bits of this same toxic protein," Collins says. "Kids with progeria are making a lot. We're making a little bit. And as our cells get older and older they start making more."

So as some researchers focus on progeria itself, others will be looking for ways to use this new information to ward off a range of diseases associated with aging.

As for Sam, he's almost 16 now, working to become an Eagle Scout, and likes to play percussion in his school band.

"For marching band I play the giant timpani drums," Sam says. "So that's a lot of fun. And I do a little bit of snare and bongos."

Progeria often means finding a different way to do what other kids are doing, Sam says. But the disease rarely stops him.

"We designed a new snare drum that's a lot lighter and more comfortable for me," he says. "So we always keep my health in mind. But 99.9 percent of the time I get to do exactly what I want."

Sam says the most important thing people should know about him is that he has a great family and a very happy life.

Copyright 2013 NPR. To see more, visit http://www.npr.org/.

Transcript

MELISSA BLOCK, HOST:

From NPR News, this is ALL THINGS CONSIDERED. I'm Melissa Block.

ROBERT SIEGEL, HOST:

And I'm Robert Siegel. Most of the time, medical research is more like a marathon than a 100-meter dash. But today, researchers are publishing the result of a scientific sprint. It's the first treatment for an extremely rare genetic disease that causes children to age so rapidly that many die in their teens. NPR's Jon Hamilton reports that just a decade ago, scientists didn't even know what caused the disease.

JON HAMILTON, BYLINE: The disease is called progeria, and there are perhaps a hundred cases in the entire world. Children with the disease have small, fragile bodies; and can look like senior citizens by the time they finish grade school. Only a handful of researchers study progeria. One of them is Leslie Gordon, from Boston Children's Hospital in Brown University. She's medical director of the Progeria Research Foundation. And Gordon wants people to know she has another credential.

DR. LESLIE GORDON: My most important title: I am the mother of a child with progeria. His name is Sam.

HAMILTON: Sam was diagnosed in 1998, shortly before he turned 2. Gordon says even though she and her husband, Scott Berns, are doctors, back then, they knew almost nothing about this disease. And what the experts told them was discouraging.

GORDON: All children - we were told - die of heart attacks or strokes between the ages of - maybe 7 and 20 years. Nobody knew the cause. Nobody was really working on this, and we were nowhere. There was no place for us to go, to understand what was happening with our child.

HAMILTON: So Gordon and her husband set out to find the cause, and a cure. They started a foundation. Gordon began doing research. But things might have gone slowly without some help from a scientist named Francis Collins. He's not just any scientist. These days, Collins runs the National Institutes of Health. Back then, he was in charge of the government's efforts to map the human genome. And Collins says early in his career, he had an experience that very few doctors have.

DR. FRANCIS COLLINS: I had a patient with progeria. And it was a fascinating circumstance - but a very frustrating one because there was nothing much known about the disease. And so I didn't quite know what to offer to this wonderful young woman.

HAMILTON: The woman died in her 20s. But Collins never forgot her.

COLLINS: And then I met Leslie and her husband, Scott, and learned that they had a son with this condition.

HAMILTON: So Collins joined a consortium of genetic scientists, set up by Gordon's foundation. He also asked a researcher in his lab to look for a genetic cause of the disease. He gave her a year.

COLLINS: And in substantially less than a year, we had the answer - by a combination of a very good post-doc and a pretty good strategy, and a little good luck along the way.

HAMILTON: The cause was a single, chance mutation on a single gene. Just one misplaced letter - out of billions in the genetic code - was responsible for a toxic protein that made cells age prematurely. Finding the cause of a genetic disease does not necessarily lead to a treatment. But in this case, Collins says, scientists had spent decades studying the gene where the error occurred.

COLLINS: And it was really, within only a short time after realizing what the problem was, that we also were able to make a hypothesis about what might help.

HAMILTON: All that happened about five years after Leslie Gordon's son, Sam, was diagnosed. Gordon says by this time, Sam was in grade school and living a pretty normal life.

GORDON: Sam was acting like his age, and he had friends his own age. He was just much, much, much smaller than the rest of his friends. And yes, he had no hair, but that doesn't matter to your friends. And so he was going to school and growing up, and doing - actually, fantastic.

HAMILTON: Even so, Gordon knew she was in a race against time. Researchers thought they knew what sort of drug might protect cells from the toxic protein that causes progeria. Developing a drug like that from scratch, could have taken many years. But by chance, drug companies had some candidates already in production. Gordon says these were experimental cancer drugs that just happened to affect the same process involved in progeria.

GORDON: Again, we got lucky because there was 10 years' worth of pharmaceutical research into developing a drug that we asked to move over to the field of progeria.

HAMILTON: But the progeria team needed help from someone who understood these unusual cancer drugs. Enter Mark Kieran, a pediatric brain cancer specialist from Boston Children's Hospital.

DR. MARK KIERAN: There were only a couple of people in the world that had been testing these drugs, and one of them was me.

HAMILTON: Kieran says by the time he got involved - around 2006 - the researchers had already shown that a drug called lonafarnib, could help mice with the progeria gene.

KIERAN: They now had all of the science. What they had never done before, was actually figure out how to move it into the clinic to treat kids. And since that's what I do every day, that's where we were able to put our - kind of expertise together, to make this thing happen.

HAMILTON: It happened fast. The study began in 2007, and was designed to run for several years. It included 28 children from 16 countries - including Leslie Gordon's son, Sam. The results are being published electronically today, in the "Proceedings of the National Academy of Science." And they are encouraging. Overall, lonafarnib helped children gain weight, and improve their bone structure. But more important, Gordon says, it has reversed changes in blood vessels associated with the heart attacks and strokes that usually kill kids with progeria.

GORDON: That was an absolutely home run, pivotal finding for our study.

HAMILTON: This drug isn't a cure. But Gordon says it's an important first step. And she notes that researchers have already moved on to a second study, using lonafarnib and two other drugs. The race against progeria has been run to benefit just a few dozen children around the globe. But there's been an unexpected payoff for the rest of humanity. NIH director Francis Collins says research on the toxic protein responsible for progeria, is changing scientists' understanding of how normal cells age.

COLLINS: It has told us something pretty profound; namely, that all of us are making little bits of this same, toxic protein. Kids with progeria are making a lot. We're making a little bit. And as our cells get older and older, they start making more.

HAMILTON: So as some researchers focus on progeria itself, others will be looking for ways to use this new information to ward off a range of diseases associated with aging. As for Leslie Gordon's son, Sam, he's almost 16 now. He's working to become an Eagle Scout, and likes to play percussion in his school band.

SAM: For marching band, I play the giant - like, timpani drums. So that's a lot of fun. And I do a little bit of snare and bongos for that.

HAMILTON: Sam says progeria often means finding a different way to do what other kids are doing.

SAM: We designed like, a new snare drum that's a lot lighter and more comfortable for me. So - you know, we always keep my health in mind, and we always want to make sure that I'm OK. But - you know, 99.9 percent of the time, I get to do exactly what I want.

HAMILTON: Sam says the most important thing people should know about him, is that he has a great family and a very happy life. Jon Hamilton, NPR News.

(SOUNDBITE OF MUSIC)

BLOCK: This is NPR. Transcript provided by NPR, Copyright NPR.

Related Program